Tuesday, May 3rd, 2016

Cognitive Impairment Pipeline Market Companies Involved in Therapeutics Development are AbbVie Inc., Addex Therapeutics Ltd, AgeneBio Inc., Amarantus Bioscience Holdings, Inc., Astellas Pharma Inc., AstraZeneca Plc, Avineuro Pharmaceuticals, Inc., Avraham Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cardax Pharmaceuticals, Inc., Cerecor Inc., CereSpir Incorporated, Cognition Therapeutics, Inc., Confluence Pharmaceuticals LLC, Coronis Partners Ltd., Cortice Biosciences, Inc., D-Pharm Ltd., Eisai Co., Ltd., Eli Lilly and Company, Ensol Biosciences Inc., F. Hoffmann-La Roche Ltd., FORUM Pharmaceuticals Inc., Genzyme Corporation, H. Lundbeck A/S, Heptares Therapeutics Limited, Intra-Cellular Therapies, Inc., Iproteos S.L., Luc Therapeutics, Inc., Merck & Co., Inc., Nanotherapeutics, Inc., Neuralstem, Inc., Neuron Biopharma SA, Octapharma AG, Omeros Corporation, Pacific Northwest Biotechnology, LLC, Panacea Pharmaceuticals, Inc., Pfizer Inc., Pherin Pharmaceuticals, Inc., Sage Therapeutics, Inc., Saniona AB, SeneXta Therapeutics SA, Shire Plc, SK Biopharmaceuticals Co., Ltd., Spherium Biomed S.L., Sunovion Pharmaceuticals Inc., Suven Life Sciences Ltd., Takeda Pharmaceutical Company Limited, Tetra Discovery Partners LLC, Therapix Biosciences Ltd, Vanda Pharmaceuticals Inc., Vicore Pharma AB and Virogenomics BioDevelopment, Inc.

Get discount on this research report at http://www.rnrmarketresearch.com/contacts/discount?rname=539815

The report provides comprehensive information on the therapeutics under development for Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cognitive Impairment and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Complete research report of 289 pages with TOC is available at http://www.rnrmarketresearch.com/cognitive-impairment-pipeline-review-h1-2016-market-report.html


- The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment

- The report reviews pipeline therapeutics for Cognitive Impairment by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Cognitive Impairment therapeutics and enlists all their major and minor projects

- The report assesses Cognitive Impairment therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Cognitive Impairment

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cognitive Impairment pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

File Library

Contact Profile

RnR Market Research

About Us:  

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us: 

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed

Ritesh Tiwari
P: + 1 888 391 5441
W: www.rnrmarketresearch.com/


Cognitive Impairment Therapeutic Products under Development, Key Players in Cognitive Impairment Therapeutics, Cognitive Impairment Pipeline Overview, Cognitive Impairment Pipeline, Cognitive Impairment Pipeline Assessment




More Formats

View QR Code